Drug Trial Radar · NCT05608681
A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
117
Planned (sponsor's estimate)
Start
Mar 31, 2023
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Eupraxia Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1b/2 study to explore the safety, efficacy and pharmacokinetics of EP-104GI in adults with eosinophilic esophagitis (EoE). Endoscopic and histologic assessments will also be evaluated to understand the local effects of EP-104GI on eosinophilic EoE disease activity. Approximately 27 to 33 participants will be enrolled in dose escalation: 3-6 participants per dose cohort. The number of participants enrolled in escalation will depend on the number of dose escalation cohorts evaluated, and dose cohorts needing to be expanded. An additional 10-24 participants will be enrolled in 1 or 2 cohorts of 10-12 participants each at tolerable dose regimen(s) selected based on the accumulated clinical data to identify the recommended phase 2 dose(s) (RP2D). In the Phase 2 randomized dose optimization portion of the study, approximately 120 subjects will be randomized to Dose A (120 mg total dose), Dose B (160 mg total dose), or matching vehicle control, with an overall assignment ratio of 1:1:1. The total number of participants in both portions of the study will be approximately 160. The study involves 8-10 site visits spread over approximately 52 weeks. Participants in an extended PK sub study will have up to 4 additional visits, to a maximum of 108 weeks post-dose. The participants will either receive the active study drug (EP-104GI) or matching vehicle control. Matching vehicle control will be used only in randomized dose optimization portion of the study. Participants randomized to receive vehicle control may receive EP-104GI (Dose A or Dose B) following the completion of Week 24 providing they meet eligibility criteria for crossover to EP-104GI. Participants randomized to receive EP-104GI on Day 0 will not receive EP-104GI or vehicle control at Week 24. The study drug or matching vehicle control will be administered by qualified personnel during an esophagogastroduodenoscopy (EGD) procedure at the Baseline/Dosing visit. Safety will be assessed throughout the study. Blood and urine samples will be collected at site visits for laboratory assessments and to measure plasma levels of EP-104GI. Participants will complete questionnaires to assess symptoms of dysphagia and odynophagia and will undergo 3-5 EGDs with esophageal biopsies at the Baseline, Week 4 (dose escalation phase only), Week 12, Week 24 (randomized dose optimization phase only), Week 26, and Week 52 (randomized dose optimization phase only).
Conditions
- Eosinophilic Esophagitis
Interventions
EP-104GIDrug
Extended-release fluticasone propionate \[FP\] for injectable suspension for gastrointestinal administration, Powder suspended in vehicle
Matching vehicle controlOther
A sterile liquid containing sterile water and excipients necessary to prepare a uniform suspension of the powder.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation- Incidence of treatment emergent adverse events (TEAEs)Time frame: 52 weeks
- Dose Escalation- Severity of treatment emergent adverse events (TEAEs)Time frame: 52 weeks
- Dose Escalation- Change from baseline in morning serum cortisol levelsTime frame: 52 weeks
- Dose Escalation- Plasma concentrations of fluticasone propionateTime frame: 108 weeks
- Dose Escalation- Change from baseline in physical examination results, BMI and weight change.Time frame: 12 weeks
- Randomised Dose Optimization- Change from baseline in EoEHSS grade and stage scored in 3 regions of the esophagus within the injection area (proximal, mid, distal)Time frame: 24 weeks
Locations
33 sites in 6 countries. Site status is shown where the registry gives one.
Campbelltown Private Hospital
Sydney, New South Wales, Australia · Recruiting
Mater Hospital Brisbane
Brisbane, Queensland, Australia · Active not recruiting
Princess Alexandra Hospital
Brisbane, Queensland, Australia · Recruiting
Coastal Digestive Health
Maroochydore, Queensland, Australia · Recruiting
Royal Adelaide Hospital
Adelaide, South Australia, Australia · Recruiting
Lyell McEwin Hospital
Elizabeth Vale, South Australia, Australia · Recruiting
Tennyson Centre Day Hospital
Kurralta Park, South Australia, Australia · Recruiting
Eastern Health Box Hill
Box Hill, Victoria, Australia · Recruiting
Northern Hospital Epping
Epping, Victoria, Australia · Recruiting
The Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Royal Melbourne Hospital
Parkville, Victoria, Australia · Recruiting
St John of God Midland
Midland, Washington, Australia · Recruiting
University of Calgary
Calgary, Alberta, Canada · Recruiting
South Edmonton Gastroenterology Research Clinic
Edmonton, Alberta, Canada · Recruiting
G.I. Research Institute
Vancouver, British Columbia, Canada · Recruiting
Brampton Gastroenterology Research Group Inc.
Brampton, Ontario, Canada · Recruiting
Charlton Digestive Disease Centre
Hamilton, Ontario, Canada · Active not recruiting
McMaster University
Hamilton, Ontario, Canada · Recruiting
West GTA Research Inc.
Mississauga, Ontario, Canada · Active not recruiting
TIDHI Innovation Inc.
Toronto, Ontario, Canada · Recruiting
McGill University Health Center
Montreal, Quebec, Canada · Recruiting
Amsterdam UMC
Amsterdam, Netherlands · Active not recruiting
Erasmus University Medical Center
Holland, Netherlands · Active not recruiting
Waikato Hospital
Hamilton, New Zealand · Active not recruiting
Capital Coast and Hutt
Lower Hutt, New Zealand · Recruiting
Aotearoa Clinical Trials
Papatoetoe, Auckland, New Zealand · Recruiting
Universitätsspital Zürich
Zurich, Switzerland · Recruiting
Cardiff and Vale University Health Board-Wales
Cardiff, United Kingdom · Recruiting
Royal Liverpool University Hospital
Liverpool, United Kingdom · Active not recruiting
St George's University of London
London, United Kingdom · Recruiting
Cambridge University Hospitals NHS Foundation Trust
Cambridge, Cambridgeshire, United Kingdom · Recruiting
Norfolk and Norwich University Hospital
Norwich, Norfolk, United Kingdom · Recruiting
Belfast Trust
Belfast, Northern Ireland, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.